Abstract Number: 2609 • 2019 ACR/ARP Annual Meeting
Anti-angiogenic VEGF-A165b Is Associated with Systemic Sclerosis Peripheral Vasculopathy
Background/Purpose: The anti-angiogenic isoform of Vascular Endothelial Growth Factor-A (VEGF-A165b) has been implicated in Systemic sclerosis (SSc) vasculopathy. High frequency ultrasound (HFUS) is a novel…Abstract Number: 2610 • 2019 ACR/ARP Annual Meeting
Relationship Between Parenchymal and Vascular Features in Systemic Sclerosis-Interstitial Lung Disease: Results from Quantitative Analysis of Chest Computed Tomography
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension negatively impact on Systemic sclerosis (SSc) prognosis. Chest computed tomography (CT) is the gold standard in…Abstract Number: 2611 • 2019 ACR/ARP Annual Meeting
Mesenchymal Stem Cells in Scleroderma: A Systematic Review
Background/Purpose: Scleroderma (systemic scleroderma or systemic sclerosis, SSc), is a highly heterogeneous autoimmune disease of unknown etiology, with a high rate of therapeutic failure and…Abstract Number: 2612 • 2019 ACR/ARP Annual Meeting
Minocycline for Refractory Calcinosis in Systemic Sclerosis: A Single-Centre Observational Cohort Study
Background/Purpose: Calcinosis represents a major challenge for patients with systemic sclerosis (SSc) for which there is no standard therapy. Minocycline has been proposed for treatment…Abstract Number: 2613 • 2019 ACR/ARP Annual Meeting
Hsp90 as a Potential Biomarker of Lung and Skin Involvement in Patients with Systemic Sclerosis
Background/Purpose: Our previous study demonstrated that Hsp90 is overexpressed in the skin of patients with systemic sclerosis (SSc), in cultured SSc fibroblasts and preclinical models…Abstract Number: 2614 • 2019 ACR/ARP Annual Meeting
Association of Body Composition in Scleroderma Patients with Disease Activity, Serum Levels of Inflammatory Cytokines and Parameters of Nutrition and Lipid Metabolism
Background/Purpose: Fibrosis of the skin and visceral organs, especially digestive tract, and musculoskeletal involvement in systemic sclerosis (SSc) can have a negative impact on body…Abstract Number: 2615 • 2019 ACR/ARP Annual Meeting
Cumulative Incidence, Survival and Predictors of Pulmonary Arterial Hypertension in Disease Subsets of Systemic Sclerosis: PAH Is Not Increased in Limited vs Diffuse Patients by Adjusted Competing Risk Analysis
Background/Purpose: Pulmonary arterial hypertension (PAH) is a life-threatening complication of systemic sclerosis (SSc), thought to be more commonly found among the limited cutaneous (lcSSc) compared…Abstract Number: 2616 • 2019 ACR/ARP Annual Meeting
Forced Vital Capacity Trajectories for Systemic Sclerosis-associated Interstitial Lung Disease—Analysis from the University of Michigan Scleroderma Cohort
Background/Purpose: Interstitial Lung Disease (ILD) is the leading cause of morbidity and mortality in systemic sclerosis (SSc) patients. Forced Vital Capacity (FVC, recorded as %…Abstract Number: 2617 • 2019 ACR/ARP Annual Meeting
Responsiveness to Change of the Modified Rodnan Skin Score in a Phase I/II Double-Blind Randomized Placebo-Controlled Trial
Background/Purpose: Modified Rodnan skin score (mRSS) is used as primary and secondary outcome measure in different trials of diffuse cutaneous systemic sclerosis (dcSSc) 1. As…Abstract Number: 2618 • 2019 ACR/ARP Annual Meeting
Anti-RNPC-3 Antibodies Are Associated with Nuclear Speckled Immunofluorescence Pattern and Enriched in Triple Negative Systemic Sclerosis Patients
Background/Purpose: Anti-nuclear antibodies (ANA) are present in approximately 90% of sera from systemic sclerosis (SSc) patients and play an important diagnostic and prognostic role in…Abstract Number: 2619 • 2019 ACR/ARP Annual Meeting
Rituximab for Eosinophilic Granulomatosis with Polyangiitis: A Systematic Review of Observational Studies
Background/Purpose: More than 40 studies containing data about adults affected by EGPA treated with Rituximab (RTX) have been published in the last decade. Nevertheless, due…Abstract Number: 2620 • 2019 ACR/ARP Annual Meeting
Effects of Tofacitinib Suppressed Pulmonary Vascular Remodeling of Allergic Vasculitis in a Murine Model
Background/Purpose: We reported allergic granulomatous vasculitis with eosinophil infiltration in an asthma model of C57BL/6 sensitized with ovalbumin (OVA). TGF-btea and IL-6 are thought to…Abstract Number: 2621 • 2019 ACR/ARP Annual Meeting
Association Between Outcome Renal, Clinical Variables and Findings of Renal Biopsy in Patients with ANCA Vasculitis
Background/Purpose: In associated ANCA vasculitis (AAV), rapidly progressive glomerulonephritis (GN) is one of the most serious complications. In 40% of cases they progress to chronic…Abstract Number: 2622 • 2019 ACR/ARP Annual Meeting
A Single Center Retrospective Analysis of Efficacy and Safety Between Low-Dose versus High-Dose Rituximab as Remission Induction Therapy with ANCA-Associated Vasculitis
Background/Purpose: Rituximab therapy for ANCA-associated vasculitis (AAV) patients was covered by insurance from 2013 in Japan. Administration of four once-weekly doses of 375 mg/m2 rituximab…Abstract Number: 2623 • 2019 ACR/ARP Annual Meeting
Abnormality of Percentages and Absolute Numbers of CD4+ Memory and Regulatory T Subset Cells in ANCA-associated Vasculitis
Background/Purpose: CD4+ T cell subsets control immune system in check and prevent autoimmunity by keeping a balance among them. However, their levels of blood in ANCA-associated vasculitis (AAV), especially absolute…
ACR Meeting Abstracts